Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences (TUMS), School of Public Health, Tehran, Iran.
Tuberculosis/HIV Research Directorate, Ethiopian Public Health Institute, Addis Ababa, Ethiopia.
PLoS One. 2020 Feb 26;15(2):e0229284. doi: 10.1371/journal.pone.0229284. eCollection 2020.
Limited evidence exists on the treatment outcome and factors that are associated with the duration from the initiation of treatment to death or treatment failure in children with drug resistant tuberculosis (DR-TB). Thus, we aimed to determine the proportion of treatment enrollment, status of treatment outcome and determine factors that are associated with the duration from treatment initiation to death or treatment failure in children treated for DR-TB in Ethiopia.
We conducted a retrospective cohort study in children younger than 15 years old who were treated for DR-TB from February 2009 to February 2019 in Ethiopia. We collected data on socio-demographic and clinical characteristics from clinical charts, registration books and laboratory result reports on 155 children. Proportion of enrollment to the treatment was calculated by dividing the total number of children who were receiving the treatment by the total number of DR-TB patients treated during the specified years. We used Cox proportional hazard models to determine factors that were associated with the duration from the beginning of the treatment to death or treatment failure. Data was analyzed using STATA version 14.
Of the 3,478 DR-TB patients enrolled into the treatment and fulfilling our inclusion criteria during the past ten years, 155 (4.5%) were children. Of the 155 children, 75 (48.4%) completed the treatment and 51 (32.9%) were cured. Furthermore, 18 (11.6%) children were died, seven (4.5%) lost to follow up and treatment of four (2.6%) children was failed. The overall treatment success was 126 (81.3%). Age younger than 5 years old [Adjusted Hazard Ratio (AHR) = 3.2, 95%CI (1.2-8.3)], HIV sero-reactivity [AHR = 5.3, 95%CI (1.8-14.9)] and being anemic [AHR = 4.3, 95%CI (1.8-10.3)] were significantly associated with the duration from the enrollment into the treatment to death or treatment failure.
In this study, the proportion of children enrolled into DR-TB treatment was lower than the proportion of adults enrolled to the treatment (4.5% in children versus 95.5% in adults) in last ten years. Our findings also suggest that children with DR-TB can be successfully treated with standardized long term regimen. Further prospective cohort study is required to investigate factors contributing to death or treatment failure.
关于耐药结核病(DR-TB)儿童从开始治疗到死亡或治疗失败的时间的治疗结果和相关因素,证据有限。因此,我们旨在确定在埃塞俄比亚接受 DR-TB 治疗的儿童中,治疗登记比例、治疗结局状况,并确定与从开始治疗到死亡或治疗失败的时间相关的因素。
我们对 2009 年 2 月至 2019 年 2 月期间在埃塞俄比亚接受 DR-TB 治疗的年龄在 15 岁以下的儿童进行了回顾性队列研究。我们从临床病历、登记册和实验室结果报告中收集了 155 名儿童的社会人口学和临床特征数据。通过将接受治疗的儿童总数除以特定年份接受治疗的 DR-TB 患者总数,计算治疗登记比例。我们使用 Cox 比例风险模型确定与从开始治疗到死亡或治疗失败的时间相关的因素。使用 STATA 版本 14 进行数据分析。
在过去十年中,共有 3478 名接受治疗并符合纳入标准的 DR-TB 患者,其中 155 名(4.5%)为儿童。在这 155 名儿童中,75 名(48.4%)完成了治疗,51 名(32.9%)治愈。此外,18 名(11.6%)儿童死亡,7 名(4.5%)失访,4 名(2.6%)儿童治疗失败。总体治疗成功率为 126 名(81.3%)。年龄小于 5 岁[调整后的危险比(AHR)=3.2,95%CI(1.2-8.3)]、HIV 阳性反应[AHR=5.3,95%CI(1.8-14.9)]和贫血[AHR=4.3,95%CI(1.8-10.3)]与从登记治疗到死亡或治疗失败的时间显著相关。
在这项研究中,过去十年中登记接受 DR-TB 治疗的儿童比例低于登记接受成人治疗的比例(儿童为 4.5%,成人为 95.5%)。我们的研究结果还表明,患有 DR-TB 的儿童可以通过标准化的长期方案成功治疗。需要进一步的前瞻性队列研究来调查导致死亡或治疗失败的因素。